PMID- 23835793
OWN - NLM
STAT- MEDLINE
DCOM- 20140612
LR  - 20131024
IS  - 1791-2431 (Electronic)
IS  - 1021-335X (Linking)
VI  - 30
IP  - 3
DP  - 2013 Sep
TI  - High CCR6/CCR7 expression and Foxp3+ Treg cell number are positively related to 
      the progression of laryngeal squamous cell carcinoma.
PG  - 1380-90
LID - 10.3892/or.2013.2603 [doi]
AB  - Chemokine receptors CCR6 and CCR7 have been reported to play important roles in T 
      cell migration and organ-specific metastasis of various tumors. In the present 
      study, we evaluated the expression and clinical significance of CCR6, CCR7, their 
      ligands and CD4+CD25+Foxp3+ regulatory T cells in laryngeal squamous cell 
      carcinoma (LSCC) and metastatic lymph nodes (LNs). The expression of CCR6, CCR7 
      and their ligands mRNA (CCL20, CCL19/CCL21) as well as the CCR6 and CCR7 proteins 
      were detected by real-time RT-PCR and immunohistochemistry (IHC), respectively. 
      Flow cytometry was used to investigate the percentage of CD4+CD25+Foxp3+ 
      regulatory T cells (Tregs) in peripheral blood mononuclear cells (PBMCs). 
      Furthermore, a number of cytokines, including interleukin (IL)-2, IL-4, IL-10, 
      IL-12p70, interferon (IFN)-gamma and transforming growth factor (TGF)-beta1 were 
      detected by ELISA. The results showed that CCR6 and CCR7 were expressed in tumors 
      in situ, metastatic LNs and CD4+CD25+Foxp3+ Tregs. It was hypothesized that the 
      expression profile of CCR6, CCR7 and the proliferation of CD4+CD25+Foxp3+ Tregs 
      affected the process of LN metastasis in LSCC patients. Therefore, the increased 
      percentage of the Foxp3+ Tregs and the upregulation of Foxp3 expression on CCR6+ 
      Tregs in LSCC patients may have accounted for the downregulation of antitumor 
      immunity in these patients, which could be valuable for assessment of prognosis 
      in LSCC treatment.
FAU - Chen, Bin
AU  - Chen B
AD  - Department of Otolaryngology, Eye Ear Nose and Throat Hospital, Fudan University, 
      Shanghai 200031, P.R. China.
FAU - Zhang, Duo
AU  - Zhang D
FAU - Zhou, Jian
AU  - Zhou J
FAU - Li, Qing
AU  - Li Q
FAU - Zhou, Lin
AU  - Zhou L
FAU - Li, Shi-Min
AU  - Li SM
FAU - Zhu, Li
AU  - Zhu L
FAU - Chou, Kuang-Yen
AU  - Chou KY
FAU - Zhou, Liang
AU  - Zhou L
FAU - Tao, Lei
AU  - Tao L
FAU - Lu, Li-Ming
AU  - Lu LM
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20130708
PL  - Greece
TA  - Oncol Rep
JT  - Oncology reports
JID - 9422756
RN  - 0 (CCR6 protein, human)
RN  - 0 (CCR7 protein, human)
RN  - 0 (Cytokines)
RN  - 0 (FOXP3 protein, human)
RN  - 0 (Forkhead Transcription Factors)
RN  - 0 (RNA, Messenger)
RN  - 0 (Receptors, CCR6)
RN  - 0 (Receptors, CCR7)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Carcinoma, Squamous Cell/*immunology/metabolism/pathology
MH  - Cytokines/genetics/metabolism
MH  - Disease Progression
MH  - Enzyme-Linked Immunosorbent Assay
MH  - Female
MH  - Flow Cytometry
MH  - Follow-Up Studies
MH  - Forkhead Transcription Factors/*metabolism
MH  - Humans
MH  - Immunoenzyme Techniques
MH  - Laryngeal Neoplasms/*immunology/metabolism/pathology
MH  - Lymphatic Metastasis
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Grading
MH  - Neoplasm Staging
MH  - Prognosis
MH  - RNA, Messenger/genetics
MH  - Real-Time Polymerase Chain Reaction
MH  - Receptors, CCR6/*metabolism
MH  - Receptors, CCR7/*metabolism
MH  - Reverse Transcriptase Polymerase Chain Reaction
MH  - Survival Rate
MH  - T-Lymphocytes, Regulatory/*immunology/metabolism
EDAT- 2013/07/10 06:00
MHDA- 2014/06/13 06:00
CRDT- 2013/07/10 06:00
PHST- 2013/03/12 00:00 [received]
PHST- 2013/05/13 00:00 [accepted]
PHST- 2013/07/10 06:00 [entrez]
PHST- 2013/07/10 06:00 [pubmed]
PHST- 2014/06/13 06:00 [medline]
AID - 10.3892/or.2013.2603 [doi]
PST - ppublish
SO  - Oncol Rep. 2013 Sep;30(3):1380-90. doi: 10.3892/or.2013.2603. Epub 2013 Jul 8.